Carbiotix

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Carbiotix announced on December 7, 2023 that the board had decided on the Rights Issue, subject to the approval of the extraordinary general meeting. On January 10, 2024, the extraordinary general meeting decided to approve the board's decision.

The Company today announces that the Company has increased the guarantee from the previous total of approximately SEK 11.2 million to a total of approximately SEK 14.2 million SEK through a guarantee at the level from 60 percent to 76.2 percent. The guarantee has been provided by external investors. The total commitment through pre-subscription- and guarantee commitments in the Rights Issue therefore amounts to approximately SEK 14.2 million (corresponding to approximately 76.2 percent of the issue volume in the Rights Issue).

For issued guarantee commitments at the level from 60 percent to 76.2 percent, a guarantee commission of 17 percent of the guaranteed amount is paid in cash compensation, alternatively an optional compensation of 22 percent in the form of units (which are subscribed at the same price as units in the Rights Issue). For the previously known guarantee commitments, compensation of 15 percent of the guaranteed amount is paid in cash compensation, alternatively an optional compensation of 20 percent in the form of units (which are subscribed for at the same price as units in the Rights Issue).

No compensation is paid for the pre-subscription commitments. Pre-subscription commitments and guarantee commitments are not secured by advance transaction, bank guarantee or similar arrangements.

For more information about Carbiotix and the Rights Issue, please refer to the memorandum drawn up and published by the Company on January 16, 2024. The memorandum, containing complete terms and consitions, is available on the Company's website (www.carbiotix.com), Sedermera Corporate Finance AB's (www.sedermera.se), Nordic Issuing AB's (www.nordicissuing.se) and Spotlight Stock Market's (www.spotlightstockmarket.com) respective websites.

Advisors
In connection with the Rights Issue, Carbiotix has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent.

For further information about the Rights Issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

For more information about the Company, please contact:
Erik Deaner, CEO
Phone: +46 (0)73-867 30 85
E-mail: erik.deaner@carbiotix.com

This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out above on 18 January 2024.

Important information
This press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants, subscription rights, BTU’s or other securities in Carbiotix AB investors should not subscribe for or acquire any securities other than on the basis of the information in the information document that will be made public before the start of the subscription period in the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be unlawful. Nor does this press release constitute an offer to sell new shares, warrants, subscription rights, BTU’s or other securities to any person in a jurisdiction where it would not be permitted to make such an offer to such a person or where such action would require prospectus, additional registration or other measures than under Swedish law. The information document, the application form and other documents relating to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires measures referred to in the previous sentence or where they would be contrary to the rules of such country. Actions contrary to this instruction may constitute a violation of applicable securities laws.

Neither shares, warrants, subscription rights, BTU’s nor any other securities have been or will be registered under the United States Securities Act of 1933 in its current wording (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

This press release may contain certain forward-looking statements that reflect the Company's current views on future events and financial and operational development. Words such as "intends", " estimates", "expects", "may", "plans", "believes", " anticipates" and other expressions that imply indications or predictions of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By nature, forwardlooking statements involve known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments and actual outcomes may differ materially from those expressed in forward-looking statements. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revisions to any forwardlooking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or the rules of Spotlight Stock Market.

About Carbiotix
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services.